> For the complete documentation index, see [llms.txt](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md).
# Immune Effects
WFA's immune relevance extends beyond direct tumour-cell killing. The most important work so far suggests that it can reduce immunosuppressive myeloid signalling, promote more favourable immune infiltration, and sensitise some tumours to checkpoint blockade.
This evidence is still preclinical. No completed human trial has defined WFA's immune effects in cancer patients.
### State of the evidence
Most immune data comes from mechanistic work and animal models. The strongest translational signal comes from syngeneic lung cancer models where WFA improved response to anti-PD-L1 therapy.
That makes the immune story promising, not settled.
### MDSC and tumour-associated macrophage modulation
Myeloid-derived suppressor cells and tumour-associated macrophages are central to tumour immune evasion.
WFA reduces MDSC production of `IL-10` and reactive oxygen species. Those changes matter because MDSCs often suppress T-cell function through oxidative and cytokine-mediated mechanisms.
WFA also reduces macrophage secretion of `IL-6` and `TNF-α`, which can otherwise reinforce an immunosuppressive microenvironment.
### CD4+ and CD8+ T-cell effects
In a murine mammary tumour model, oral WFA reduced tumour burden and increased intratumoural and splenic `CD4+` helper T-cell proportions.
In a syngeneic NSCLC model, WFA increased `CD8+` T-cell infiltration when paired with anti-PD-L1 therapy. That combination exceeded either agent alone.
The exact T-cell pattern may be model-dependent, but the direction of effect supports immune microenvironment reshaping rather than simple immune suppression.
### Checkpoint inhibitor sensitisation
This is the most clinically interesting immune mechanism so far.
WFA induces immunogenic cell death in NSCLC models. That means tumour-cell death is accompanied by danger signalling that can activate dendritic cells and promote adaptive immune engagement.
WFA also increases tumour-cell `PD-L1` expression through ROS-mediated signalling. On its own, that can look counterintuitive. In the right context, it may increase tumour susceptibility to anti-PD-L1 therapy.
That is what has been observed in mouse models. WFA sensitised an otherwise resistant lung cancer model to anti-PD-L1 treatment without additional weight loss or obvious toxicity.
### Dendritic cells
In vitro work supports dendritic cell activation downstream of WFA-induced immunogenic cell death. This strengthens the checkpoint-sensitisation rationale.
### Neutrophils
No peer-reviewed evidence currently defines WFA's effect on tumour-associated neutrophils. This remains a meaningful gap.
### Summary of immune evidence status
| Immune cell or effect | Evidence level |
| --------------------------------------------- | --------------------------------------- |
| MDSC suppression (`IL-10`, ROS) | Mechanistic and in vitro confirmed |
| TAM cytokine modulation (`IL-6`, `TNF-α`) | Mechanistic and in vitro confirmed |
| `CD4+` T-cell increase in tumour | Animal-supported |
| `CD8+` T-cell increase in combination therapy | Animal-supported |
| Immunogenic cell death induction | In vitro confirmed and animal-supported |
| Checkpoint inhibitor sensitisation | Animal-supported |
| Dendritic cell activation | In vitro confirmed |
| Human immune data | None available |
### Clinical take
WFA's immune profile is interesting because it may help in two ways at once. It can reduce tumour-intrinsic survival signalling and weaken parts of the suppressive microenvironment around the tumour.
The most credible combination use case at present is with checkpoint blockade, especially in tumours where baseline resistance is driven by poor immune activation and suppressive myeloid tone.
### Related pages
* [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md)
* [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md)
### Key references
Noh K. H. et al. — MDSC and macrophage modulation, including reduced myeloid suppressor function with WFA.\
Oral Administration of Withaferin A Increases Infiltration of CD4+ T Cells and Reduces Tumor Burden in a Mouse Mammary Tumor Model — CD4+ T-cell changes with oral WFA in breast cancer.\
Banerjee S. et al. — immunogenic cell death, PD-L1 up-regulation, and checkpoint sensitisation in NSCLC.\
Qiao J. et al. — WFA as a phytochemical checkpoint sensitiser in the broader ICI literature.\
Singh N. et al. — broader overview of WFA and *Withania somnifera* immunomodulatory actions.\
Access and availability:\
Source: MCS Formulas, “Withaferin A Pro Liposomal.”\
`50 mg` WFA per capsule. Available via healthcare professional request.\
### In this section
#### Core pages
* [Withaferin A (WFA) in Oncology](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology.md)
* [Evidence Summary](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/evidence-summary.md)
* [Anticancer Mechanisms](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/anti-cancer-mechanisms.md)
* [Immune Effects](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md)
* [Synergistic Combinations](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/synergistic-combinations.md)
#### Cancer-type pages
* [WFA Evidence by Cancer Type](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type.md)
* [Breast Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/breast-cancer.md)
* [Ovarian Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/ovarian-cancer.md)
* [Non-Small Cell Lung Cancer](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/non-small-cell-lung-cancer.md)
* [Glioblastoma](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/glioblastoma.md)
* [Other Cancer Types](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/wfa-evidence-by-cancer-type/other-cancer-types.md)
#### Practical pages
* [Pharmacokinetics & Metabolism](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/pharmacokinetics-and-metabolism.md)
* [Sourcing Quality](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/sourcing-quality.md)
* [Safety, Interactions and WFA Dosing](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/safety-interactions-and-wfa-dosing.md)
* [Hormones — ER-α and Androgens](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/hormones-er-a-and-androgens.md)
* [Terrain Support — Liposomal WFA vs Whole-Plant Ashwagandha](/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/terrain-support-liposomal-wfa-vs-whole-plant-ashwagandha.md)
{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}
{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}
---
# Agent Instructions
This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com.
## Querying This Documentation
If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.
Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter:
```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/natural-medicines/withaferin-a-wfa-in-oncology/immune-effects.md?ask=&goal=
```
`ask` is the immediate question: it should be specific, self-contained, and written in natural language.
`goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.
Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.